Early molecular changes in Alzheimer disease: Can we catch the disease in its presymptomatic phase?

Journal of Alzheimer's Disease

Volumn 38, Issue 4, 2014, Pages 719-740

  Wirz, Kerstin T S ^a   Keitel, Stella ^a   Swaab, Dick F ^a   Verhaagen, Joost ^a,b   Bossers, Koen ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Alzheimer disease; Amyloid beta protein; Cerebrovascular disorders; DNA damage; Energy metabolism; Insulin; Mitochondrial membranes; Oxidative stress; Physiopathology; Synaptic transmission

Indexed keywords

ANTIOXIDANT; BETA SECRETASE 1; CASPASE 3; CHOLESTEROL; COPPER; ENDONUCLEASE; ENDOTHELIN CONVERTING ENZYME; FREE RADICAL; GAMMA SECRETASE; GANGLIOSIDE; GELATINASE A; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MITOCHONDRIAL DNA; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID; PROTEIN BCL XL; PYRUVIC ACID; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SPHINGOMYELIN; STREPTOZOCIN; TAU PROTEIN; ZINC; ZINC TRANSPORTER;

AGING; ALZHEIMER DISEASE; AMNESIA; ANGIOGENESIS; ANTERIOR CINGULATE; APOPTOSIS; ATTENTION; AUTOPHOSPHORYLATION; BINDING SITE; BLOOD BRAIN BARRIER; BLOOD LEVEL; BLOOD VESSEL TONE; BLOOD VESSEL WALL; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN CORTEX; BRAIN HOMOGENATE; BRAIN ISCHEMIA; BRAIN METABOLISM; BRAIN REGION; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CELL DEATH; CELL FRACTIONATION; CELL MEMBRANE; CEREBELLUM CORTEX; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CYTOSKELETON; CYTOTOXICITY; DEGENERATION; DEMENTIA; DENDRITIC SPINE; DETERIORATION; DIFFERENTIATION; DISEASE COURSE; DISEASE DURATION; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENDOTHELIAL DYSFUNCTION; ENERGY EXPENDITURE; ENERGY METABOLISM; ENERGY RESOURCE; EXCITOTOXICITY; EXTRACELLULAR MATRIX; FIBROBLAST; FOLLOW UP; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLIA CELL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GOLGI COMPLEX; GROWTH; HEART ARREST; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; HOMEOBOX; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOXIA; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRACELLULAR SPACE; LEARNING; LIPID COMPOSITION; LIPID PEROXIDATION; LIPID RAFT; LONG TERM DEPRESSION; MACROPHAGE; MEMORY; MEMORY CONSOLIDATION; MESENCHYME; METABOLIC RATE; MEYNERT BASAL NUCLEUS; MICROGLIA; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOCHONDRION; MULTIPHOTON MICROSCOPY; NEGATIVE FEEDBACK; NEOCORTEX; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARENCHYMA; PASSIVE AVOIDANCE; PENTOSE PHOSPHATE CYCLE; PERFUSION; PERFUSION WEIGHTED IMAGING; PHOSPHOLIPID METABOLISM; PLASMA; POSITIVE FEEDBACK; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC DENSITY; POSTSYNAPTIC MEMBRANE; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATION; RESPIRATORY CHAIN; REVIEW; RISK FACTOR; SEIZURE; SMOOTH MUSCLE FIBER; SODIUM CELL LEVEL; SPIN LABELING; SURVIVAL; SYNAPSE; SYNAPTIC MEMBRANE; SYNAPTIC TRANSMISSION; URINE; VASCULAR AMYLOIDOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASODILATATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CEREBROVASCULAR DISORDERS; DNA DAMAGE; ENERGY METABOLISM; INSULIN; MITOCHONDRIAL MEMBRANES; OXIDATIVE STRESS; PHYSIOPATHOLOGY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; ASYMPTOMATIC DISEASES; DNA DAMAGE; EARLY DIAGNOSIS; HUMANS; NEUROFIBRILLARY TANGLES; OXIDATIVE STRESS; PLAQUE, AMYLOID;

EID: 84890534541     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130920     Document Type: Review

References (301)

1. World Health Organization and Alzheimer's Disease International (2012) Dementia: A public health priority. World Health Organization, http://www.who.int/mental health/pu blications/dementia report 2012/en/
2. Batsch N, Mittelman M (2012) World Alzheimer Report 2012. Alzheimers Dis Int, http://www.alz.co.uk/research/wo rld-report-2012.
3. Ferretti MT, Cuello AC (2011) Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 8, 164-174.
4. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51, 145-155.
5. Schon EA, Area-Gomez E (2010) Is Alzheimer's disease a disorder of mitochondria-associated membranes? J Alzheimers Dis 20(Suppl 2), S281-S292.
6. Dubelaar EJ, Mufson EJ, ter Meulen WG, Van Heerikhuize JJ, Verwer RW, Swaab DF (2006) Increased metabolic activity in nucleus basalis of Meynert neurons in elderly individuals with mild cognitive impairment as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 65, 257-266.
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
8. Cartier L, Hartley O, Dubois-Dauphin M, Krause K-H (2005) Chemokine receptors in the central nervous system: Role in brain inflammation and neurodegenerative diseases. Brain Res Rev 48, 16-42.
9. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJM, Rozemuller AJM, van Gool WA (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: Neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8, 142-150.
10. Swaab DF, Bao A-M (2011) (Re-)activation of neurons in aging and dementia: Lessons from the hypothalamus. Exp Gerontol 46, 178-184.
11. Wu L, Rosa-Neto P, Hsiung G, Sadovnick A, Masellis M, Black S, Jia J, Gauthier S (2012) Early-onset familial Alzheimer's disease (EOFAD). Can J Neurol Sci 39, 436-445.
12. Hellström-Lindahl E, Viitanen M, Marutle A (2009) Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. Neurochem Int 55, 243-252.
13. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak- Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
14. Tol J, Roks G, Slooter AJ, van DuijnCM(1999) Genetic and environmental factors in Alzheimer's disease. Rev Neurol (Paris) 155(Suppl 4), S10-S16.
15. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al- Chalabi A, ShawCE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel K-H, Klopp N, Wichmann H-E, CarrasquilloMM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
16. Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues J-F, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P (2009) Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
17. Bertram L, Tanzi R (2004) The current status of Alzheimer's disease genetics: What do we tell the patients? Pharmacol Res 50, 385-396.
18. Kamboh M (2004) Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 68, 381-404.
19. Serretti A, Artioli P, Quartesan R, De Ronchi D (2005) Genes involved in Alzheimer's disease, a survey of possible candidates. J Alzheimers Dis 7, 331-353.
20. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
21. Morris JC (2005) Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 19, 163-165.
22. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.
23. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR (2000) "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology 55, 370-376.
24. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Leon M De, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367, 1262-1270.
25. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer diseaseassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404.
26. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800.
27. Shankar GM, Walsh DM (2009) Alzheimer's disease: Synaptic dysfunction and Abeta. Mol Neurodegener 4, 48.
28. Arriagada P, Growdon J, Hedley-Whyte E, Hyman B (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
29. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500.
30. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66, 1469-1475.
31. Vlassenko AG, Benzinger TLS, Morris JC (2012) PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta 1822, 370-379.
32. De Calignon A, Fox LM, Pitstick R, Carlson G a, Bacskai BJ, Spires-Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464, 1201-1204.
33. de la Torre JC (2011) Three postulates to help identify the cause of Alzheimer's disease. J Alzheimers Dis 24, 657-668.
34. García-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI (2003) Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimers Dis 5, 65-77.
35. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
36. Joseph J, Shukitt-hale B, Denisova NA, Martin A, Perry G, Smith MA (2001) Copernicus revisited: Amyloid beta in Alzheimer's disease. Neurobiol Aging 22, 131-146.
37. Lee H, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007) Amyloid-beta in Alzheimer disease: The null versus the alternate hypotheses. J Pharmacol Exp Ther 321, 823-829.
38. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114, 121-130.
39. Holmes C, Boche D, Wilkinson D, Yadegarfar G, HopkinsV, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR(2008) Long-term effects ofAβ42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 11-14.
40. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
41. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, CuelloAC(2010)Anovel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 20, 113-126.
42. de la Monte SM (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 9, 35-66.
43. Candeias E, Duarte AI, Carvalho C, Correia SC, Cardoso S, Santos RX, Plácido AI, Perry G, Moreira PI (2012) The impairment of insulin signaling in Alzheimer's disease. IUBMB Life 64, 951-957.
44. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, De Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
45. Gasparini L, Netzer WJ, Greengard P, Xu H (2002) Does insulin dysfunction play a role in Alzheimer's disease? TRENDS Pharmacol Sci 23, 288-293.
46. Talbot K, Wang H, Kazi H, Han L, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
47. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB (2008) Insulin resistance and Alzheimer's disease: Molecular links&clinical implications. Curr Alzheimer Res 5, 438-447.
48. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease relationship to severity of dementia and . Neurology 50, 164-168.
49. Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S, Zöchling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105, 423-438.
50. Roriz-Filho JS, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves MLF, Moriguti JC, Roriz-Cruz M (2009) (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792, 432-443.
51. Molina JA, Jiménez-Jiménez FJ, Vargas C, Gómez P, de Bustos F, Gómez-Escalonilla C, Zurdo M, Tallón A, Martínez-Salio A, Porta-Etessam J, Villanueva C, Arenas J (2002) Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol Scand 106, 347-350.
52. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21, 2561-2570.
53. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8, 1390-1397.
54. Di Carlo M, Picone P, Carrotta R, Giacomazza D, San Biagio PL (2010) Insulin promotes survival of amyloid-beta oligomers neuroblastoma damaged cells via caspase 9 inhibition and Hsp70 upregulation. J Biomed Biotechnol 2010, 147835.
55. Messier C, Teutenberg K (2005) The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 12, 311-328.
56. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14, 1015-1022.
57. Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E (2002) Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis 4, 369-374.
58. Zhao W-Q, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260.
59. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, MattsonMP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19, 1205-1219.
60. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel M, a, Plymate SR, Breitner JCS, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
61. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29-38.
62. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlí T, Spanò A, Gallo D, Mungari P, Consoli D, Bosco D (2010) Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 288, 112-116.
63. Vance JE (1990) Phospholipid synthesis in a membrane fraction associated with mitochondria. J Biol Chem 265, 7248-7256.
64. Browman DT, Resek ME, Zajchowski LD, Robbins SM (2006) Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci 119, 3149-3160.
65. Fujimoto M, Hayashi T, Su T-P (2012) The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria. Biochem Biophys Res Commun 417, 635-639.
66. Hayashi T, Fujimoto M (2010) Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol Pharmacol 77, 517-528.
67. Vance JE (1991) Newly made phosphatidylserine and phosphatidylethanolamine are preferentially translocated between rat liver mitochondria and endoplasmic reticulum. J Biol Chem 266, 89-97.
68. Camandola S, MattsonMP(2011) Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim Biophys Acta 1813, 965-973.
69. Pani A, Mandas A, Diaz G, Abete C, Cocco PL, Angius F, Brundu A, Muçaka N, Pais ME, Saba A, Barberini L, Zaru C, Palmas M, Putzu PF, Mocali A, Paoletti F, La Colla P, Dessì S (2009) Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease. BMC Med 7, 66.
70. Schon EA, Area-Gomez E (2012) Mitochondria-associated ER membranes in Alzheimer disease. Mol Cell Neurosci 55, 26-36.
71. Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X (2010) Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease? Mol Neurobiol 41, 87-96.
72. Area-Gomez E, de Groof AJC, Boldogh I, Bird TD, Gibson GE, Koehler CM, Yu WH, Duff KE, Yaffe MP, Pon LA, Schon EA (2009) Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol 175, 1810-1816.
73. Chyung JH, Raper DM, Selkoe DJ (2005) Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem 280, 4383-4392.
74. Cupers P, Bentahir M, Craessaerts K, Orlans I, Vanderstichele H, Saftig P, De Strooper B, Annaert W (2001) The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. J Cell Biol 154, 731-740.
75. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, Moechars D, Bollen M, Fraser P, George-Hyslop PS, Van Leuven F (1997) Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem 272, 3590-3598.
76. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJC, Madra M, Ikenouchi J, Umeda M, Bird TD, Sturley SL, Schon EA (2012) Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J 31, 4106-4123.
77. Atamna H, Frey WH (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7, 297-310.
78. Yan MH, Wang X, Zhu X (2013) Mitochondrial defects and oxidative stress in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 62, 90-101.
79. GrimmMOW, Zinser EG, Grösgen S, Hundsdörfer B, Rothhaar TL, Burg VK, Kaestner L, Bayer TA, Lipp P, Müller U, Grimm HS, Hartmann T (2012) Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer's disease pathology with ganglioside metabolism. PloS One 7, e34095.
80. Yuyama K, Yanagisawa K (2010) Sphingomyelin accumulation provides a favorable milieu for GM1 gangliosideinduced assembly of amyloid beta-protein. Neurosci Lett 481, 168-172.
81. Crino PB, Ullman MD, Vogt BA, Bird ED, Volicer L (1989) Brain gangliosides in dementia of the Alzheimer type. Arch Neurol 46, 398-401.
82. Pernber Z, Blennow K, Bogdanovic N, Månsson J-E, BlomqvistM(2012) Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. Dement Geriatr Cogn Disord 33, 174-188.
83. Fischer VW, Siddiqi A, Yusufaly Y (1990) Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol 79, 672-679.
84. KalariaR(1996) Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 72, 193-214.
85. Kalaria R (2002) Small vessel disease and Alzheimer's dementia: Pathological considerations. Cerebrovscular Dis 13, 48-52.
86. Perlmutter LS (1994) Microvascular pathology and vascular basement membrane components in Alzheimer's disease. Mol Neurobiol 9, 33-40.
87. Nicolakakis N, Hamel E (2011) Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab 31, 1354-1370.
88. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO (2004) Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro- CAA position statement. Neurobiol Aging 25, 589-597; discussion 603-604.
89. Jellinger KA (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis 7, 112-115.
90. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV (2005) Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 11, 959-965.
91. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-1222.
92. Vermeer SE, Longstreth WT, Koudstaal PJ (2007) Silent brain infarcts: A systematic review. Lancet Neurol 6, 611-619.
93. Wisniewski HM, Wegiel J, VorbrodtAW, Mazur-Kolecka B, Frackowiak J (2000) Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci 903, 6-18.
94. Frackowiak J, Miller DL, Potempska A, Sukontasup T, Mazur-Kolecka B (2003) Secretion and accumulation of Abeta by brain vascular smooth muscle cells from AbetaPPSwedish transgenic mice. J Neuropathol Exp Neurol 62, 685-696.
95. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
96. Kanekiyo T, Liu C-C, Shinohara M, Li J, Bu G (2012) LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J Neurosci 32, 16458-16465.
97. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112, 405-415.
98. Parikh NA, Katsetos CD, Ashraf QM, Haider SH, Legido A, Delivoria-Papadopoulos M, Mishra OP (2003) Hypoxiainduced caspase-3 activation and DNA fragmentation in cortical neurons of newborn piglets: Role of nitric oxide. Neurochem Res 28, 1351-1357.
99. Broughton BRS, Reutens DC, Sobey CG (2009) Apoptotic mechanisms after cerebral ischemia. Stroke 40, e331-e339.
100. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W (2006) Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103, 18727-18732.
101. an Groen T, Puurunen K, Mäki H-M, Sivenius J, Jolkkonen J (2005) Transformation of diffuse beta-amyloid precursor protein and beta-amyloid deposits to plaques in the thalamus after transient occlusion of the middle cerebral artery in rats. Stroke 36, 1551-1556.
102. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW (2004) Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009, 1-8.
103. Wiśniewski HM, Maślińska D (1996) Beta-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol 34, 65-71.
104. Jendroska K, Poewe W, Daniel SE, Pluess J, Iwerssen- Schmidt H, Paulsen J, Barthel S, Schelosky L, Cervós- Navarro J, DeArmond SJ (1995) Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 90, 461-466.
105. Qi J-P, Wu H, Yang Y, Wang D-D, Chen Y-X, Gu Y-H, Liu T (2007) Cerebral ischemia and Alzheimer's disease: The expression of amyloid-beta and apolipoprotein E in human hippocampus. J Alzheimers Dis 12, 335-341.
106. Zetterberg H, Mörtberg E, Song L, Chang L, Provuncher GK, Patel PP, Ferrell E, Fournier DR, Kan CW, Campbell TG, Meyer R, Rivnak AJ, Pink BA, Minnehan KA, Piech T, Rissin DM, Duffy DC, Rubertsson S, Wilson DH, Blennow K (2011) Hypoxia due to cardiac arrest induces a timedependent increase in serum amyloid β levels in humans. PloS One 6, e28263.
107. Bibl M, Welge V, Schmidt H, Esselmann H, Mollenhauer B, Lewczuk P, Otto M, Kornhuber J, Wiltfang J (2012) Plasma amyloid-beta peptides in acute cerebral ischemia: A pilot study. J Clin Lab Anal 26, 238-245.
108. Qian L, Ding L, Cheng L, Zhu X, Zhao H, Jin J, Guan D, Zhang B, Chen X, Xu Y (2012) Early biomarkers for post-stroke cognitive impairment. J Neurol 259, 2111-2118.
109. Wang Z, Yang D, Zhang X, Li T, Li J, Tang Y, LeW(2011) Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PloS One 6, e19229.
110. Nalivaevaa NN, Fisk L, Kochkina EG, Plesneva SA, Zhuravin IA, Babusikova E, Dobrota D, Turner AJ (2004) Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. Ann N Y Acad Sci 1035, 21-33.
111. Grammas P, Tripathy D, Sanchez A, Yin X, Luo J (2011) Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. Int J Clin Exp Pathol 4, 616-627.
112. Johnson N, Jahng G-H, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology 234, 851-859.
113. Dorr A, Sahota B, Chinta LV, Brown ME, Lai AY, Ma K, Hawkes C, a, McLaurin J, Stefanovic B (2012) Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Brain 135, 3039-3050.
114. Miao J, Xu F, Davis J, Otte-Höller I, Verbeek MM, Van Nostrand WE (2005) Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol 167, 505-515.
115. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130, 2310-2319.
116. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ (2002) Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study. Neurology 58, 1629-1634.
117. Rensink AAM, de Waal RMW, Kremer B, Verbeek MM (2003) Pathogenesis of cerebral amyloid angiopathy. Brain Res Rev 43, 207-223.
118. Iwasaki K, Egashira N, Hatip-Al-Khatib I, Akiyoshi Y, Arai T, Takagaki Y, Watanabe T, Mishima K, FujiwaraM(2006) Cerebral ischemia combined with beta-amyloid impairs spatial memory in the eight-arm radial maze task in rats. Brain Res 1097, 216-223.
119. Koistinaho M, Kettunen MI, Goldsteins G, Keinänen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J (2002) Beta-amyloid precursor protein transgenic mice that harbor diffuseAbeta deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation. Proc Natl Acad Sci U S A 99, 1610-1615.
120. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
121. Jomova K, Vondrakova D, Lawson M, ValkoM(2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345, 91-104.
122. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156.
123. Liochev SI, Fridovich I (1999) Superoxide and iron: Partners in crime. IUBMB Life 48, 157-161.
124. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58, 730-735.
125. Smith MA, Perry G, Richey PL, Sayre LM, And erson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. Nature 382, 120-121.
126. Aluise CD, Robinson RAS, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: Insights into memory loss in MCI. J Alzheimers Dis 23, 257-269.
127. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, Perluigi M, Mancuso C, Butterfield DA (2011) Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis 25, 623-633.
128. Sultana R, Perluigi M, Newman SF, Pierce WM, Cini C, Coccia R, Butterfield DA (2010) Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox Signal 12, 327-336.
129. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease. Neurobiol Dis 22, 223-232.
130. Frederikse PH, Garland D, Zigler JS, Piatigorsky J (1996) Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 271, 10169-10174.
131. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P (1995) Nonenzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1, 693-699.
132. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, SmithMA(2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
133. Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21, 4183-4187.
134. Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D (2010) Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med 13, 37-43.
135. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52, 562-565.
136. Praticò D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA (2000) Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48, 809-812.
137. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44, 410-413.
138. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6, 93-97.
139. Duits FH, Kester MI, Scheffer PG, Blankenstein MA, Scheltens P, Teunissen CE, van der Flier WM (2013) Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers. J Alzheimers Dis 36, 563-570.
140. Aluise CD, Robinson RAS, Beckett TL, MurphyMP, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2010) Preclinical Alzheimer disease: Brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39, 221-228.
141. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
142. Reddy PH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease. J Neurochem 96, 1-13.
143. Smith M, Zhu X, Tabaton M, Liu G, Mckeel D Jr, Cohen M (2010) increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19, 363-372.
144. McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 23, 2212-2217.
145. Bush AI (2012) The metal theory of Alzheimer's disease. J Alzheimers Dis 33, 277-281.
146. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA (2010) Alterations of zinc transporter proteins ZnT-1, ZnT- 4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol 20, 343-350.
147. Bossers K, Wirz KTS, MeerhoffGF, EssingAHW, van Dongen JW, Houba P, Kruse CG, Verhaagen J, Swaab DF (2010) Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 133, 3699-3723.
148. Smith MA (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868.
149. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura M (2007) Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 43, 1552-1559.
150. Liu D, Pitta M, Jiang H, Lee J-H, Zhang G, Chen X, Kawamoto EM, MattsonMP(2013) Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: Evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging 34, 1564-1580.
151. Brasnjevic I, Hof PR, Steinbusch HWM, Schmitz C (2008) Accumulation of nuclear DNA damage or neuron loss: Molecular basis for a new approach to understanding selective neuronal vulnerability in neurodegenerative diseases. DNA Repair 7, 1087-1097.
152. Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G (2008) Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 44, 1493-1505.
153. Canugovi C, Yoon JS, Feldman NH, Croteau DL, Mattson MP, Bohr VA (2012) Endonuclease VIII-like 1 (NEIL1) promotes short-term spatial memory retention and protects from ischemic stroke-induced brain dysfunction and death in mice. Proc Natl Acad Sci U S A 109, 14948-14953.
154. Day JJ, Sweatt JD (2011) Epigenetic mechanisms in cognition. Neuron 70, 813-829.
155. Gräff J, Kim D, Dobbin MM, Tsai L-H (2011) Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 91, 603-649.
156. Rass U, Ahel I, West SC (2007) Defective DNA repair and neurodegenerative disease. Cell 130, 991-1004.
157. Wang J, Markesbery WR, Lovell MA (2006) Increased oxidative damage in nuclear and mitochondrialDNAin mild cognitive impairment. J Neurochem 96, 825-832.
158. Shackelford DA (2006) DNA end joining activity is reduced in Alzheimer's disease. Neurobiol Aging 27, 596-605.
159. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747-751.
160. Mullaart E, Boerrigter ME, Ravid R, Swaab DF, Vijg J (1990) Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11, 169-173.
161. Myung N-H, Zhu X, Kruman II, Castellani RJ, Petersen RB, Siedlak SL, Perry G, Smith MA, Lee H (2008) Evidence of DNA damage in Alzheimer disease: Phosphorylation of histone H2AX in astrocytes. Age (Dordr.) 30, 209-215.
162. Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus- Nahrmann Y, Scheithauer M-O, Rettinger G, Otto M, Tumani H, Thal DR, Attems J, Jellinger KA, Kestler HA, von Arnim CAF, Rudolph KL (2012) Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 78, 569-577.
163. Correale J, Fiol M (2011) Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler 17, 521-531.
164. Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, KreitzerAC, Mucke L (2013) Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β. Nat Neurosci 16, 613-621.
165. Hoyer S (2004) Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: Therapeutic implications. Adv Exp Med Biol 541, 135-152.
166. Kapogiannis D, Mattsion MP (2011) Perturbed energy metabolism and neuronal circuit dysfunction in cognitive impairment. Lancet Neurol 10, 187-198.
167. Mamelak M (2012) Sporadic Alzheimer's disease: The starving brain. J Alzheimers Dis 31, 459-474.
168. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32, 486-510.
169. Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147, 180-195.
170. Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong C-X (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-1832.
171. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications. Ann Neurol 57, 695-703.
172. Salehi A, Swaab DF (1999) Diminished neuronal metabolic activity in Alzheimer's disease. Review article. J Neural Transm 106, 955-986.
173. Parihar MS, Brewer GJ (2007) Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 292, C8-23.
174. Fouquet M, Desgranges B, Landeau B, Duchesnay E, Mézenge F, de la Sayette V, Viader F, Baron J-C, Eustache F, Chételat G (2009) Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain 132, 2058-2067.
175. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of theNINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
176. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen L a, McKeelDW, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56, 127-129.
177. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501-1508.
178. Scheff SW, Price DA (2006) Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. J Alzheimers Dis 9, 101-115.
179. DeKosky S, Scheff S, Styren S (1996) Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration 5, 417-421.
180. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
181. Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63, 1155-1162.
182. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27, 1372-1384.
183. Sze C-I, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ (2000) Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 175, 81-90.
184. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
185. Heffernan JM, Eastwood SL, Nagy Z, Sanders MW, McDonald B, Harrison PJ (1998) Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp Neurol 150, 235-239.
186. Masliah E, Ellisman M, Carragher B, Mallory M, Young S, Hansen L, DeTeresa R, Terry R (1992) Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. J Neuropathol Exp Neurol 51, 404-414.
187. Wakabayashi K, Honer WG, Masliah E (1994) Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res 667, 24-32.
188. Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VMY (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351.
189. Hall G, Chu B, Lee G, Yao J (2000) Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease. J Cell Sci 113, 1373-1387.
190. Thies E, Mandelkow E-M (2007) Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 27, 2896-2907.
191. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan L-L, Ashe KH, Liao D (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081.
192. Schindowski K, Bretteville A, Leroy K, Bégard S, Brion J-P, Hamdane M, Buée L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616.
193. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
194. Klyubin I, Cullen WK, Hu N-W, Rowan MJ (2012) Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain 5, 25.
195. Nimmrich V, Ebert U (2009) Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric β-amyloid. Rev Neurosci 20, 1-12.
196. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's diseaseaffected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100, 10417-10422.
197. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200.
198. Klein WL, Stine WB, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25, 569-580.
199. KesselsHW, Nguyen LN, Nabavi S, Malinow R (2010) The prion protein as a receptor for amyloid-beta. Nature 466, E3-4; discussion E4-5.
200. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R (2010) Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13, 190-196.
201. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058.
202. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H (2010) A mouse model of amyloid beta oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30, 4845-4856.
203. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
204. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA (2006) Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: An independent component analysis. J Neurosci 26, 10222-10231.
205. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand- Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404-411.
206. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, Sperling RA (2004) Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 56, 27-35.
207. Hämäläinen A, Pihlajamäki M, Tanila H, Hänninen T, Niskanen E, Tervo S, Karjalainen PA, Vanninen RL, Soininen H (2007) Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging 28, 1889-1903.
208. Kircher TT, Weis S, Freymann K, Erb M, Jessen F, Grodd W, Heun R, Leube DT (2007) Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J Neurol Neurosurg Psychiatry 78, 812-818.
209. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66, 435-440.
210. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, TanilaH(2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29, 3453-3462.
211. Palop JJ, Chin J, Roberson ED, Wang J, ThwinMT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711.
212. Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA (2004) Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 367, 164-167.
213. Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, Malter JS (2008) Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol 1, 157-168.
214. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M (2012) Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74, 467-474.
215. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu G-Q, Palop JJ, Mucke L (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad SciUSA109, E2895-E2903.
216. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922.
217. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37, 925-937.
218. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118, 167-179.
219. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI (2010) Cognitive loss in zinc transporter-3 knock-out mice: A phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci 30, 1631-1636.
220. Bjorklund NL, Reese LC, Sadagoparamanujam V-M, Ghirardi V, Woltjer RL, Taglialatela G (2012) Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer's disease neuropathology. Mol Neurodegener 7, 23.
221. Sensi SL, Paoletti P, Koh J-Y, Aizenman E, Bush AI, Hershfinkel M (2011) The neurophysiology and pathology of brain zinc. J Neurosci 31, 16076-16085.
222. Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM (2010) Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 5, 15.
223. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 64, 718-726.
224. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, IrizarryMC(2004) β-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164, 719-725.
225. Hong HS, Hwang EM, Sim HJ, Cho H-J, Boo JH, Oh SS, Kim SU, Mook-Jung I (2003) Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 307, 922-927.
226. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10, 279-288.
227. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, Perry G, Tabaton M (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92, 628-636.
228. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F (2005) Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2, 22.
229. Barman A, Prabhakar R (2012) Protonation states of the catalytic dyad of β-secretase (BACE1) in the presence of chemically diverse inhibitors: A molecular docking study. J Chem Inf Model 52, 1275-1287.
230. Zhang C (2012) Natural compounds that modulate BACE1- processing of amyloid-beta precursor protein in Alzheimer's disease. Discov Med 14, 189-197.
231. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8, 1343-1349.
232. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, De, Reynolds CH, ToungeBA, Luo C, Scott MK, Huang Y, Braeken M, Pieters SMA, Berthelot DJC, Masure S, Bruinzeel WD, Jordan AD, Parker MH, Boyd RE, Qu J, Alexander RS, Brenneman DE, Reitz AB (2007) 2-Amino-3, 4-dihydroquinazolines as inhibitors of BACE- 1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 50, 4261-4264.
233. Cumming JN, Smith EM, Wang L, Misiaszek J, Durkin J, Pan J, Iserloh U, Wu Y, Zhu Z, Strickland C, Voigt J, Chen X, Kennedy ME, Kuvelkar R, Hyde LA, Cox K, Favreau L, Czarniecki MF, Greenlee WJ, McKittrick BA, Parker EM, StamfordAW(2012) Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett 22, 2444-2449.
234. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH), http://www.clinicaltrials.gov/ct2/show/ NCT01739348?term =mk-8931&rank=3, Last updated August 9, 2013, Accessed on August 15, 2013.
235. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE (2011) Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31, 16507-16516.
236. Sankaranarayanan S, Price EA, Wu G, Crouthamel M-C, Shi X-P, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 324, 957-969.
237. Chang AM, Halter JB (2003) Aging and insulin secretion. Am J Physiol Endocrinol Metab 284, E7-12.
238. Centers for Disease Control, and Prevention (2011) National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, USA.
239. Kushner JA (2013) The role of aging upon β cell turnover. J Clin Invest 123, 990-995.
240. Conley KE, Marcinek DJ, Villarin J (2007) Mitochondrial dysfunction and age. Curr Opin Clin Nutr Metab Care 10, 688-692.
241. Seo AY, Joseph A-M, Dutta D, Hwang JCY, Aris JP, Leeuwenburgh C (2010) New insights into the role of mitochondria in aging: Mitochondrial dynamics and more. J Cell Sci 123, 2533-2542.
242. Marín J (1995) Age-related changes in vascular responses: A review. Mech Ageing Dev 79, 71-114.
243. Bohr V, Anson RM, Mazur S, Dianov G (1998) Oxidative DNA damage processing and changes with aging. Toxicol Lett 102-103, 47-52.
244. Hamilton ML, Van Remmen H, Drake JA, Yang H, Guo ZM, Kewitt K, Walter CA, Richardson A (2001) Does oxidative damage to DNA increase with age? Proc Natl Acad Sci U S A 98, 10469-10474.
245. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429, 883-891.
246. Rutten BP, Schmitz C, Gerlach OH, Oyen HM, deMesquita EB, Steinbusch HW, Korr H (2007) The aging brain: Accumulation of DNA damage or neuron loss? Neurobiol Aging 28, 91-98.
247. Rutten BPF, Korr H, Steinbusch HWM, Schmitz C (2003) The aging brain: Less neurons could be better. Mech Ageing Dev 124, 349-355.
248. Roberts SB, Rosenberg I (2006) Nutrition and aging: Changes in the regulation of energy metabolism with aging. Physiol Rev 86, 651-667.
249. Salmon AB (2012) Oxidative stress in the etiology of ageassociated decline in glucose metabolism. Longev Heal 1, 7.
250. Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain. Nat Rev Neurosci 7, 30-40.
251. Driscoll I, Howard SR, Stone JC, Monfils MH, Tomanek B, BrooksWM, Sutherland RJ (2006) The aging hippocampus: A multi-level analysis in the rat. Neuroscience 139, 1173-1185.
252. McGahon BM, Martin DS, Horrobin DF, Lynch MA (1999) Age-related changes in synaptic function: Analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 94, 305-314.
253. Ojo B, Rezaie P, Gabbott PL, Davies H, Colyer F, Cowley TR, Lynch M, Stewart MG (2012) Age-related changes in the hippocampus (loss of synaptophysin and glial-synaptic interaction) are modified by systemic treatment with an NCAM-derived peptide, FGL. Brain Behav Immun 26, 778-788.
254. Rosenzweig ES, Barnes CA (2003) Impact of aging on hippocampal function: Plasticity, network dynamics, and cognition. Prog Neurobiol 69, 143-179.
255. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
256. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903, 222-228.
257. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging 27, 451-458.
258. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A 102, 18694-18699.
259. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26, 9057-9068.
260. Li H, Dhanasekaran P, Alexander ET, Rader DJ, Phillips MC, Lund-Katz S (2013) Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels. Arterioscler Thromb Vasc Biol 33, 687-693.
261. Elosua R, Ordovas JM, Cupples LA, Fox CS, Polak JF, Wolf PA, D'Agostino RA Sr, O'Donnell CJ (2004) Association of APOE genotype with carotid atherosclerosis in men and women: The Framingham Heart Study. J Lipid Res 45, 1868-1875.
262. Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA (2005) APOE, vascular pathology, and the AD brain. Neurology 65, 259-265.
263. Anand SS, Xie C, Paré G, Montpetit A, Rangarajan S, McQueen MJ, Cordell HJ, Keavney B, Yusuf S, Hudson TJ, Engert JC (2009) Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet 2, 16-25.
264. Caselli RJ, Dueck AC, Locke DEC, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM (2011) Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes. Neurology 76, 1078-1084.
265. Tamaoka A, Miyatake F, Matsuno S, Ishii K, Nagase S, Sahara N, Ono S, Mori H, Wakabayashi K, Tsuji S, Takahashi H, Shoji S (2000) Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 54, 2319-2321.
266. Lind J, Persson J, Ingvar M, Larsson A, Cruts M, Van Broeckhoven C, Adolfsson R, Bäckman L, Nilsson LG, Petersson KM, Nyberg L (2006) Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers. Brain J Neurol 129, 1240-1248.
267. Trivedi MA, Schmitz TW, Ries ML, Torgerson BM, Sager MA, Hermann BP, Asthana S, Johnson SC (2006) Reduced hippocampal activation during episodic encoding in middleaged individuals at genetic risk of Alzheimer's disease: A cross-sectional study. BMC Med 4, 1.
268. Jagust WJ, LandauSM(2012) Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 32, 18227-18233.
269. Salehi A, Dubelaar EJ, Mulder M, Swaab DF (1998) Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc Natl Acad Sci U S A 95, 11445-11449.
270. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 98, 3334-3339.
271. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for lateonset Alzheimer's dementia. Proc Natl Acad Sci U S A 101, 284-289.
272. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2005) Correlations between apolipoprotein E epsilon4 gene dose and brainimaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102, 8299-8302.
273. Dubelaar EJ, Verwer RW, Hofman MA, Van Heerikhuize JJ, Ravid R, Swaab DE (2004) ApoE epsilon4 genotype is accompanied by lower metabolic activity in nucleus basalis of Meynert neurons in Alzheimer patients and controls as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 63, 159-169.
274. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW (2000) Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343, 450-456.
275. BondiMW, Houston WS, Eyler LT, BrownGG(2005) fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 64, 501-508.
276. Fleisher AS, Houston WS, Eyler LT, Frye S, Jenkins C, Thal LJ, Bondi MW (2005) Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol 62, 1881-1888.
277. Wishart HA, Saykin AJ, Rabin LA, Santulli RB, Flashman LA, Guerin SJ, Mamourian AC, Belloni DR, Rhodes CH, McAllister TW (2006) Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. Am J Psychiatry 163, 1603-1610.
278. Li Z, Zhang H, Liu J, Liang C-P, Li Y, Li Y, Teitelman G, Beyer T, Bui HH, Peake DA, Zhang Y, Sanders PE, Kuo M-S, Park T-S, Cao G, Jiang X-C (2011) Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol 31, 4205-4218.
279. Baron AD (2002) Insulin resistance and vascular function. J Diabetes Complications 16, 92-102.
280. Murray IVJ, Proza JF, Sohrabji F, Lawler JM (2011) Vascular and metabolic dysfunction in Alzheimer's disease: A review. Exp Biol Med 236, 772-782.
281. Salkovic-Petrisic M, Osmanovic-Barilar J, Brückner MK, Hoyer S, Arendt T, Riederer P (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: A long-term follow up study. J Neural Transm 118, 765-772.
282. Liu Q, Zhang J, Zerbinatti C, Zhan Y, Kolber BJ, Herz J, Muglia LJ, Bu G (2011) Lipoprotein receptor LRP1 regulates leptin signaling and energy homeostasis in the adult central nervous system. PLoS Biol 9, e1000575.
283. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3, 169-178.
284. ZhaoW, Chen H, Xu H, Moore E, Meiri N, Quon MJ, Alkon DL (1999) Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274, 34893-34902.
285. Moreira PI (2012) Alzheimer's disease and diabetes: An integrative viewof the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 30(Suppl 2), S199-S215.
286. Won SJ, Yoo BH, Kauppinen TM, Choi BY, Kim JH, Jang BG, LeeMW, Sohn M, Liu J, Swanson RA, Suh SW (2012) Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats. J Neuroinflammation 9, 182.
287. Planel E, Miyasaka T, Launey T, Chui D-H, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer's disease. J Neurosci 24, 2401-2411.
288. Ismail IH, Hendzel MJ (2008) The gamma-H2A.X: Is it just a surrogate marker of double-strand breaks or much more? Environ Mol Mutagen 49, 73-82.
289. Palmer AM (1999) The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J Neural Transm 106, 317-328.
290. Martins RN, Harper CG, Stokes GB, Masters CL (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46, 1042-1045.
291. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D (2003) The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39, 43-56.
292. Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33, 2540-2546.
293. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, ButterfieldDA(2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22, 76-87.
294. LambertMP, BarlowAK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448-6453.
295. Ziff EB (1997) Enlightening the postsynaptic density. Neuron 19, 1163-1174.
296. Gerozissis K, Kyriaki G (2003) Brain insulin: Regulation, mechanisms of action and functions. Cell Mol Neurobiol 23, 1-25.
297. Laron Z (2009) Insulin and the brain. Arch Physiol Biochem 115, 112-116.
298. Wan Q, Xiong ZG, Man HY, Ackerley CA, Braunton J, Lu WY, Becker LE, MacDonald JF, Wang YT (1997) Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 388, 686-690.
299. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricular- streptozotocin injected rodents. Neurobiol Aging 33, 430.e5-18.
300. De Felice FG, Vieira MNN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao W-Q, Ferreira ST, Klein WL (2008) Protection of synapses against Alzheimer'slinked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976.
301. Hoyer S (2000) Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: An update. Exp Gerontol 35, 1363-1372.